KRAS and neoplasm: In contrast, the Kras ASO and immRNA combination treatment exhibited a potent anti-tumor effect, presenting the lowest tumor burden in the lungs (Figure 5C) and a significantly increased rate of survival among treated mice (Figure 5D).